| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04412096 |
| P6099 | clinical trial phase | phase IV clinical trial | Q42825046 |
| P767 | contributor to the creative work or subject | Mayo Clinic | Q1130172 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2023-12-31 | |
| P921 | main subject | glaucoma | Q159701 |
| antihypertensive drug | Q575890 | ||
| beta blocker | Q816759 | ||
| (S)-(−)-timolol | Q413994 | ||
| eye disease | Q3041498 | ||
| adrenergic agent | Q50430229 | ||
| neurotransmitter agent | Q73112927 | ||
| P1050 | medical condition | glaucoma | Q159701 |
| ocular hypertension | Q9294051 | ||
| P2899 | minimum age | 30 | |
| P1132 | number of participants | 200 | |
| P4844 | research intervention | latanoprost | Q634959 |
| (S)-(−)-timolol | Q413994 | ||
| eye drop | Q552308 | ||
| P8005 | research subject recruitment status | not yet recruiting | Q76649614 |
| P580 | start time | 2020-06-30 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance |
Search more.